在慢性阶段慢性髓性白血病患者中停用伊马替尼的长期结果:全国多中心前性研究
Emine Merve Savaş1, Seda Yılmaz2, Ayşe Asena Başer Dikyar3
1Gazi University Faculty of Medicine, Department of Hematology, Ankara, Türkiye
概括
在慢性髓性白血病 (CML) 患者中停止伊马替尼是安全的,并提供经济效益. 密切监测允许在分子反应丧失的情况下重新启动治疗.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药物经济学 药物经济学
背景情况:
- 伊马替尼彻底改变了慢性髓性白血病 (CML) 的治疗方法,延长了患者的寿命.
- 改善CML患者的预期寿命将重点转移到生活质量和成本效益.
- 新出现的证据表明,一些CML患者在停止伊马替尼布后可以保持分子反应.
研究的目的:
- 评估在成人慢性阶段CML患者中停止伊马替尼的长期结果.
- 评估停止氨酸激酶抑制剂 (TKI) 治疗的安全性和有效性.
- 在国家队列中确定TKI停止的经济影响.
主要方法:
- 一项国家多中心前性队列研究,涉及4个中心的41名CML患者.
- 非随机,单臂试验,通过实时PCR重新评估分子反应.
- 停用伊马提尼布后48个月的中位随访时间.
主要成果:
- 在48个月的分子无复发生存率为33.2%.
- 在41名患者中,有27名患者失去了主要的分子反应,但在重新启动伊马替尼布后重新获得了深度分子反应.
- 停产带来了显著的国家成本节约 (大约1. 245,150美元) 的价格.
结论:
- 停止使用氨酸激酶抑制剂并进行细致的分子监测是慢性阶段CML的可行策略.
- 这种方法为国家经济带来了巨大的优势.
- 这项研究代表了在土耳其进行的第一个TKI停药试验.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K


